Citadel Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-400
| Closed | -$2.34K | – | 16078 |
|
|
2022
Q4 | $2.34K | Buy |
+400
| New | +$2.1K | ﹤0.01% | 14349 |
|
|
2021
Q3 | – | Sell |
-13,100
| Closed | -$55K | – | 15010 |
|
|
2021
Q2 | $55K | Sell |
13,100
-6,800
| -34% | -$28.8K | ﹤0.01% | 13300 |
|
|
2021
Q1 | $99K | Buy |
+19,900
| New | +$161K | ﹤0.01% | 12489 |
|
|
2019
Q4 | – | Sell |
-107,600
| Closed | -$633K | – | 9976 |
|
|
2019
Q3 | $633K | Sell |
107,600
-14,000
| -12% | -$149K | ﹤0.01% | 6348 |
|
|
2019
Q2 | $1.46M | Buy |
121,600
+102,600
| +540% | +$1.1M | ﹤0.01% | 5064 |
|
|
2019
Q1 | $229K | Buy |
19,000
+7,200
| +61% | +$106K | ﹤0.01% | 8023 |
|
|
2018
Q4 | $148K | Sell |
11,800
-3,100
| -21% | -$42.8K | ﹤0.01% | 8065 |
|
|
2018
Q3 | $221K | Buy |
+14,900
| New | +$234K | ﹤0.01% | 8060 |
|
|
2016
Q1 | – | Sell |
-1,800
| Closed | -$34K | – | 8293 |
|
|
2015
Q4 | $34K | Buy |
+1,800
| New | +$39.1K | ﹤0.01% | 7590 |
|
Citadel Advisors's CNCE Position: Q1 2023 in Review
Citadel Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,391,302 shares — an estimated $8.13M sold.
Citadel Advisors first reported a position in CNCE in Q4 2014 and held it in 24 quarters. The position peaked at $8.13M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Citadel Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 1,391,302 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $8.13M.
- Citadel Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 24 quarters.
- Citadel Advisors's Concert Pharmaceuticals, Inc. position peaked at $8.13M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.